Abstract | BACKGROUND:
Alitretinoin (9-cis-retinoic acid) is a unique panagonist retinoid, capable of binding to all six known retinoid receptors (RAR-alpha, -beta, -gamma, and RXR-alpha, -beta, -gamma). Studies are being carried out to determine how best to utilize this characteristic in treatments for conditions such as chronic hand dermatitis. OBJECTIVE: METHODS: The scope of the review encompasses ways that alitretinoin is currently and may potentially be utilized. RESULTS/CONCLUSIONS:
|
Authors | Caleb Cheng, Jason Michaels, Noah Scheinfeld |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 17
Issue 3
Pg. 437-43
(Mar 2008)
ISSN: 1744-7658 [Electronic] England |
PMID | 18321241
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents
- Receptors, Retinoic Acid
- Alitretinoin
- Tretinoin
|
Topics |
- Administration, Oral
- Alitretinoin
- Antineoplastic Agents
(administration & dosage, adverse effects, pharmacology, therapeutic use)
- Hand Dermatoses
(drug therapy, metabolism)
- Humans
- Receptors, Retinoic Acid
(metabolism)
- Sarcoma, Kaposi
(drug therapy, metabolism)
- Tretinoin
(administration & dosage, adverse effects, pharmacology, therapeutic use)
|